Bicara Therapeutics (NASDAQ:BCAX) COO Sells $233,500.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $18.68, for a total transaction of $233,500.00. Following the completion of the transaction, the chief operating officer owned 189,141 shares of the company’s stock, valued at $3,533,153.88. This trade represents a 6.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ryan Cohlhepp also recently made the following trade(s):

• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.05, for a total value of $225,625.00.
• On Wednesday, October 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total value of $227,000.00.
• On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $196,854.00.
• On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $715,176.00.

Bicara Therapeutics Stock Down 1.1%

BCAX stock traded down $0.21 during midday trading on Tuesday, reaching $18.15. The stock had a trading volume of 559,497 shares, compared to its average volume of 608,338. The business has a fifty day simple moving average of $17.06 and a two-hundred day simple moving average of $13.26. The firm has a market cap of $994.29 million, a price-to-earnings ratio of -8.10 and a beta of -0.87. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $19.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently modified their holdings of the business. Tudor Investment Corp ET AL bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $296,000. Cantor Fitzgerald L. P. bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $1,579,000. XTX Topco Ltd raised its holdings in Bicara Therapeutics by 16.5% during the 3rd quarter. XTX Topco Ltd now owns 37,774 shares of the company’s stock worth $596,000 after buying an additional 5,360 shares during the period. Vestal Point Capital LP raised its holdings in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after buying an additional 100,000 shares during the period. Finally, Mariner LLC raised its holdings in Bicara Therapeutics by 403.8% during the 3rd quarter. Mariner LLC now owns 62,660 shares of the company’s stock worth $989,000 after buying an additional 50,223 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BCAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 14th. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Piper Sandler started coverage on Bicara Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Monday, November 10th. Finally, HC Wainwright dropped their price objective on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.67.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.